Autolus Therapeutics (AUTL) Registration filing summary

Company overview and business model

• Commercial-stage biopharmaceutical company focused on next-generation T cell therapies for cancer and autoimmune diseases, leveraging proprietary T cell programming technologies.

• Lead product AUCATZYL (obe-cel) approved by FDA in November 2024 for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL); commercial launches in the US (Jan 2025) and UK (Jan 2026).

• Obe-cel is also in development for pediatric B-ALL, B-NHL, and autoimmune indications, with ongoing clinical trials and promising early data.

• Manufacturing centralized at the Nucleus facility in Stevenage, UK, with Cardinal Health as US distribution partner.

Financial performance and metrics

• Financial statements for the year ended December 31, 2025, audited by Ernst & Young LLP, are incorporated by reference.

• Company voluntarily files detailed periodic reports on US domestic issuer forms, providing extensive financial disclosures.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of ADSs by the selling securityholder; proceeds from warrant exercise ($1.9314 per ADS) will be received if exercised for cash.

• Registration costs borne by the company; selling securityholder pays underwriting fees, commissions, and certain legal expenses.